KalVista Pharmaceuticals Inc [KALV] stock prices are up 2.79% to $11.81 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KALV shares have gain 0.51% over the last week, with a monthly amount drifted -23.26%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
KalVista Pharmaceuticals Inc [NASDAQ: KALV] stock has seen the most recent analyst activity on January 31, 2025, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $19. Previously, TD Cowen started tracking the stock with Buy rating on January 07, 2025, and set its price target to $30. On December 18, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $22 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $30 on June 15, 2020. SVB Leerink initiated its recommendation with an Outperform and recommended $31 as its price target on July 29, 2019. Needham started tracking with a Buy rating for this stock on March 20, 2019, and assigned it a price target of $35. In a note dated October 30, 2018, Jefferies initiated an Buy rating and provided a target price of $30 on this stock.
The stock price of KalVista Pharmaceuticals Inc [KALV] has been fluctuating between $7.30 and $17.28 over the past year. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. KalVista Pharmaceuticals Inc [NASDAQ: KALV] shares were valued at $11.81 at the most recent close of the market. An investor can expect a potential return of 91.96% based on the average KALV price forecast.
Analyzing the KALV fundamentals
Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -142.21%, Pretax Profit Margin comes in at -138.53%, and Net Profit Margin reading is -142.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.94, Equity is -1.96 and Total Capital is -1.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.44 points at the first support level, and at 11.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.09, and for the 2nd resistance point, it is at 12.37.
Ratios To Look Out For
It’s worth pointing out that KalVista Pharmaceuticals Inc [NASDAQ:KALV]’s Current Ratio is 5.37. As well, the Quick Ratio is 5.37, while the Cash Ratio is 3.24. Considering the valuation of this stock, the price to sales ratio is 417.26, the price to book ratio is 14.58.
Transactions by insiders
Recent insider trading involved Palleiko Benjamin L, CHIEF EXECUTIVE OFFICER, that happened on Sep 08 ’25 when 7294.0 shares were sold. Chief Commercial Officer, Sweeny Nicole completed a deal on Aug 25 ’25 to sell 1480.0 shares. Meanwhile, CHIEF DEVELOPMENT OFFICER Yea Christopher sold 1954.0 shares on Aug 25 ’25.
